After the patent expired, Dr. Reddy’s Laboratories entered the GLP-1 therapy market with the launch of Obeda, the first DCGI-approved generic semaglutide injection for Type 2 diabetes in India.
The company is able to launch a more accessible version of the popular diabetes therapy thanks to the Drugs Controller General of India’s permission. Obeda costs ₹4,200 per month and comes in 2 mg and 4 mg doses in pre-filled disposable pens intended for once-weekly subcutaneous treatment.
The company claims that a Phase III clinical study with 312 participants showed identical glycaemic control results and comparable safety and efficacy to the reference medication.
According to Dr. Reddy’s, all aspects of the drug’s development and production, including the active medicinal ingredient, were finished internally. Subject to regulatory permissions, the company also intends to expand the introduction of generic semaglutide to international markets.
The launch, according to CEO Erez Israeli, demonstrates the company’s commitment to growing its footprint in important therapeutic areas and improving its capacity for complicated drug development.
Source – The Economic Times
India is in talks for six FTAs to expand global trade partnerships, aiming to boost…
ISRO advances the Bharatiya Antariksh Station, with the first module costing ₹1,763 crore, boosting India’s…
West Asia conflict raises costs for India’s semiconductor ambitions, impacting supply chains, energy prices, and…
India advances indigenous air defence with Project Kusha trial success, boosting self-reliance and strengthening multi-layered…
West Asia conflict raises concerns for Indian markets, impacting oil prices, trade flows, industry stability,…